SAFETY AND EFFICACY OF COMBINATION THERAPY OF INTERFERON ΑLPHA-2 AND RUXOLITINIB IN POLYCYTHEMIA VERA AND LOW-/INTERMEDIATE-1-RISK MYELOFIBROSIS – A ONE YEAR FOLLOW-UP UPDATE OF A PHASE II STUDY

Stine Ulrik Mikkelsen, Lasse Kjær, Mads Emil Bjørn, Trine Alma Knudsen, Anders Lindholm Sørensen, Vibe Skov, Christen Bertel Lykkegaard Andersen, Ole Weiss Bjerrum, Nana Brochmann Mortensen, Daniel El Fassi, Torben Kruse, Thomas Stauffer Larsen, Hans Torben Mourits-Andersen, Claus Henrik Nielsen, Niels Pallisgaard, Mads Thomassen, Hans Carl Hasselbalch

Research output: Contribution to conference without publisher/journalConference abstract for conferenceResearchpeer-review

Original languageEnglish
Publication date15. Jun 2018
Publication statusPublished - 15. Jun 2018
EventEuropean Hematology Association 23rd congress EHA 2018 - Stockholm , Sweden
Duration: 14. Jun 201817. Jun 2018

Conference

ConferenceEuropean Hematology Association 23rd congress EHA 2018
CountrySweden
CityStockholm
Period14/06/201817/06/2018

Cite this

Mikkelsen, S. U., Kjær, L., Bjørn, M. E., Knudsen, T. A., Sørensen, A. L., Skov, V., Andersen, C. B. L., Weiss Bjerrum, O., Brochmann Mortensen, N., El Fassi, D., Kruse, T., Larsen, T. S., Mourits-Andersen, H. T., Nielsen, C. H., Pallisgaard, N., Thomassen, M., & Hasselbalch, H. C. (2018). SAFETY AND EFFICACY OF COMBINATION THERAPY OF INTERFERON ΑLPHA-2 AND RUXOLITINIB IN POLYCYTHEMIA VERA AND LOW-/INTERMEDIATE-1-RISK MYELOFIBROSIS – A ONE YEAR FOLLOW-UP UPDATE OF A PHASE II STUDY. Abstract from European Hematology Association 23rd congress EHA 2018, Stockholm , Sweden.